9th International Conference on Vaccines Research & Development
| When | Monday, November 11, 2024 - Wednesday, November 13, 2024 |
| Where | Boston United States |
| Category | Vaccine |
| Location | |
| Organised by | United Scientific Group (USG) |
| Number of Attendees | 2,750 |
| Share this page: |  |
 |
 |
 |
About the event
The Vaccines R&D 2024 conference is set to serve as a dynamic platform, fostering interdisciplinary collaboration at the cutting edge of accelerated and essential vaccine research. Across a span of three days, distinguished speakers from around the world, representing industry, academia, federal bodies, and regulatory agencies, will share groundbreaking advancements, address contemporary challenges, and provide inspirational insights and innovative lessons gained during the vaccine development process.
The Vaccines R&D 2024 conference is set to serve as a dynamic platform, fostering interdisciplinary collaboration at the cutting edge of accelerated and essential vaccine research. Across a span of three days, distinguished speakers from around the world, representing industry, academia, federal bodies, and regulatory agencies, will share groundbreaking advancements, address contemporary challenges, and provide inspirational insights and innovative lessons gained during the vaccine development process.
By Numbers
| Attendees: | 2750+ |
| Years Experience: | 10 |
| Speakers: | 935 |
Sessions
- Technology & Delivery PlatformsmRNA, Vector-based, Nanoparticle vaccines, Adjuvants and Emerging technologies
- RSV, Influenza, COVID-19RSV, Influenza, COVID-19, Pneumococcal, Tuberculosis, Whooping cough
- Vaccine DevelopmentPreclinical studies, Clinical trials, Regulatory review, Manufacturing, Quality control, Post-market surveillance
- Immune CharacterizationAntibody production, Neutralization assays, Immune markers, Cytokine profiles, mAbs
- New and EmergingZika, Ebola, Marburg, Lassa fever, Dengue
- Bacterial and ViralDTP, Pneumococcal, Meningococcal, MMR, Hepatitis, HPV, Chickenpox
- Conjugate VaccinesRecombinant, Polysaccharide, Subunit vaccines
- Manufacturing and RegulatoryAntigen production, Formulation, QC, Scale-Up, Cold Chain management
- Role of AdjuvantsImmune response, Duration of protection, Vaccine efficacy, Subunit vaccines
- Cancer, HIVPreventive, Therapeutic vaccines, Tumor antigens
- Vaccine SafetyPreclinical testing, Adverse event reporting, Regulatory approval, Vaccine hesitancy
- Clinical TrialsPhase I, II and III studies